FGENライブシグナル | Getagraph.comで利益を最大化

買う 107747 min ago

@ $2.26

発行日: 15 2月 2024 @ 05:55

リターン: -49.78%

前回のシグナル: 2月 15 - 05:23

前回のシグナル: 売る

リターン: -2.38 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	639 566
平均出来高	2.45M
時価総額	112.90M
EPS	$0 ( 2024-02-26 )
次の収益日	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.00600 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Adib Deyaa	Sell	0	Common Stock
2024-04-22	Adib Deyaa	Sell	300 000	Stock Option (Right to Buy)
2024-03-22	Wettig Thane	Sell	782	Common Stock
2024-03-07	Wettig Thane	Buy	50 000	Common Stock
2024-03-06	Graham Juan	Buy	781	Common Stock

INSIDER POWER
64.62
Last 100 transactions
Buy: 2 904 321 \| Sell: 578 976

ボリューム相関

長: 0.02 (neutral)

短: -0.40 (neutral)

Signal:(54.295) Neutral

FibroGen Inc 相関

10 最も正の相関
FCBP	0.909
SMMT	0.904
CCOI	0.901
FGM	0.897
YQ	0.893
FEP	0.89
EUFN	0.889
BNIXU	0.887
CID	0.887
NIU	0.886

10 最も負の相関
PCRX	-0.904
SLDP	-0.891
MARK	-0.887
PFBI	-0.887
WKSP	-0.885
RCMT	-0.884
NTLA	-0.882
ONDS	-0.875
LARK	-0.875
RDHL	-0.869

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

FibroGen Inc 相関 - 通貨/商品

0.42
( neutral )

0.53
( weak )

0.00
( neutral )

0.75
( moderate )

-0.55
( weak negative )

FibroGen Inc 財務諸表

Annual	2023
収益:	$147.75M
総利益:	$128.90M (87.24 %)
EPS:	$-2.92

FY	2023
収益:	$147.75M
総利益:	$128.90M (87.24 %)
EPS:	$-2.92

FY	2022
収益:	$140.73M
総利益:	$120.45M (85.59 %)
EPS:	$-3.15

FY	2021
収益:	$235.31M
総利益:	$222.44M (94.53 %)
EPS:	$-3.13

Financial Reports:

No articles found.

FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.